A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation

S. Cascinu, R. Berardi, S. Salvagni, G. D. Beretta, V. Catalano, F. Pucci, A. Sobrero, P. Tagliaferri, R. Labianca, M. Scartozzi, F. Crocicchio, E. Mari, A. Ardizzoni

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Interesting activity has been reported by combining chemotherapy with cetuximab. An alternative approach for blocking EGFR function has been the development of small-molecule inhibitors of tyrosine kinase domain such as gefitinib. We designed a multicentre phase II study in advanced colorectal cancer combining gefitinib+FOLFOX in order to determine the activity and to relate EGFR expression and gene amplification and NF-kB activation to therapeutic results. Patients received FOLFOX-4 regimen plus gefitinib as first-line treatment. Tumour samples were analysed for EGFR protein expression by immunohistochemical analysis and for EGFR gene amplification by fluorescence in situ hybridisation (FISH), chromogenic in situ hybridisation (CISH) and NF-kB activation. Forty-three patients were enrolled into this study; 15 patients experienced a partial response (response rate=34.9%), whereas other 12 (27.9%) had a stable disease. Median progression-free survival (PFS) was 7.8 months and median overall survival (OS) was 13.9 months. We did not find any relationship with EGFR overexpression, gene amplification, while NF-kB activation was associated with a resistance to therapy. Gefitinib does not seem to increase the activity of FOLFOX in advanced colorectal cancer even in patients overexpressing EGFR or with EGFR amplification. Furthermore, while NF-kB activation seems to predict resistance to chemotherapy as demonstrated 'in vitro' models, gefitinib does not overcome this mechanism of resistance, as reported for cetuximab.

Original languageEnglish
Pages (from-to)71-76
Number of pages6
JournalBritish Journal of Cancer
Volume98
Issue number1
DOIs
Publication statusPublished - Jan 15 2008

Fingerprint

NF-kappa B
Colorectal Neoplasms
erbB-1 Genes
Gene Amplification
In Situ Hybridization
Therapeutics
Drug Therapy
Fluorescence In Situ Hybridization
Protein-Tyrosine Kinases
Disease-Free Survival
gefitinib
Survival
Neoplasms
Proteins
Cetuximab

Keywords

  • Colorectal cancer
  • Gefitinib
  • NF-kB

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation. / Cascinu, S.; Berardi, R.; Salvagni, S.; Beretta, G. D.; Catalano, V.; Pucci, F.; Sobrero, A.; Tagliaferri, P.; Labianca, R.; Scartozzi, M.; Crocicchio, F.; Mari, E.; Ardizzoni, A.

In: British Journal of Cancer, Vol. 98, No. 1, 15.01.2008, p. 71-76.

Research output: Contribution to journalArticle

Cascinu, S. ; Berardi, R. ; Salvagni, S. ; Beretta, G. D. ; Catalano, V. ; Pucci, F. ; Sobrero, A. ; Tagliaferri, P. ; Labianca, R. ; Scartozzi, M. ; Crocicchio, F. ; Mari, E. ; Ardizzoni, A. / A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation. In: British Journal of Cancer. 2008 ; Vol. 98, No. 1. pp. 71-76.
@article{358568eec9334fac92b59cd064080c3e,
title = "A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation",
abstract = "Interesting activity has been reported by combining chemotherapy with cetuximab. An alternative approach for blocking EGFR function has been the development of small-molecule inhibitors of tyrosine kinase domain such as gefitinib. We designed a multicentre phase II study in advanced colorectal cancer combining gefitinib+FOLFOX in order to determine the activity and to relate EGFR expression and gene amplification and NF-kB activation to therapeutic results. Patients received FOLFOX-4 regimen plus gefitinib as first-line treatment. Tumour samples were analysed for EGFR protein expression by immunohistochemical analysis and for EGFR gene amplification by fluorescence in situ hybridisation (FISH), chromogenic in situ hybridisation (CISH) and NF-kB activation. Forty-three patients were enrolled into this study; 15 patients experienced a partial response (response rate=34.9{\%}), whereas other 12 (27.9{\%}) had a stable disease. Median progression-free survival (PFS) was 7.8 months and median overall survival (OS) was 13.9 months. We did not find any relationship with EGFR overexpression, gene amplification, while NF-kB activation was associated with a resistance to therapy. Gefitinib does not seem to increase the activity of FOLFOX in advanced colorectal cancer even in patients overexpressing EGFR or with EGFR amplification. Furthermore, while NF-kB activation seems to predict resistance to chemotherapy as demonstrated 'in vitro' models, gefitinib does not overcome this mechanism of resistance, as reported for cetuximab.",
keywords = "Colorectal cancer, Gefitinib, NF-kB",
author = "S. Cascinu and R. Berardi and S. Salvagni and Beretta, {G. D.} and V. Catalano and F. Pucci and A. Sobrero and P. Tagliaferri and R. Labianca and M. Scartozzi and F. Crocicchio and E. Mari and A. Ardizzoni",
year = "2008",
month = "1",
day = "15",
doi = "10.1038/sj.bjc.6604121",
language = "English",
volume = "98",
pages = "71--76",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation

AU - Cascinu, S.

AU - Berardi, R.

AU - Salvagni, S.

AU - Beretta, G. D.

AU - Catalano, V.

AU - Pucci, F.

AU - Sobrero, A.

AU - Tagliaferri, P.

AU - Labianca, R.

AU - Scartozzi, M.

AU - Crocicchio, F.

AU - Mari, E.

AU - Ardizzoni, A.

PY - 2008/1/15

Y1 - 2008/1/15

N2 - Interesting activity has been reported by combining chemotherapy with cetuximab. An alternative approach for blocking EGFR function has been the development of small-molecule inhibitors of tyrosine kinase domain such as gefitinib. We designed a multicentre phase II study in advanced colorectal cancer combining gefitinib+FOLFOX in order to determine the activity and to relate EGFR expression and gene amplification and NF-kB activation to therapeutic results. Patients received FOLFOX-4 regimen plus gefitinib as first-line treatment. Tumour samples were analysed for EGFR protein expression by immunohistochemical analysis and for EGFR gene amplification by fluorescence in situ hybridisation (FISH), chromogenic in situ hybridisation (CISH) and NF-kB activation. Forty-three patients were enrolled into this study; 15 patients experienced a partial response (response rate=34.9%), whereas other 12 (27.9%) had a stable disease. Median progression-free survival (PFS) was 7.8 months and median overall survival (OS) was 13.9 months. We did not find any relationship with EGFR overexpression, gene amplification, while NF-kB activation was associated with a resistance to therapy. Gefitinib does not seem to increase the activity of FOLFOX in advanced colorectal cancer even in patients overexpressing EGFR or with EGFR amplification. Furthermore, while NF-kB activation seems to predict resistance to chemotherapy as demonstrated 'in vitro' models, gefitinib does not overcome this mechanism of resistance, as reported for cetuximab.

AB - Interesting activity has been reported by combining chemotherapy with cetuximab. An alternative approach for blocking EGFR function has been the development of small-molecule inhibitors of tyrosine kinase domain such as gefitinib. We designed a multicentre phase II study in advanced colorectal cancer combining gefitinib+FOLFOX in order to determine the activity and to relate EGFR expression and gene amplification and NF-kB activation to therapeutic results. Patients received FOLFOX-4 regimen plus gefitinib as first-line treatment. Tumour samples were analysed for EGFR protein expression by immunohistochemical analysis and for EGFR gene amplification by fluorescence in situ hybridisation (FISH), chromogenic in situ hybridisation (CISH) and NF-kB activation. Forty-three patients were enrolled into this study; 15 patients experienced a partial response (response rate=34.9%), whereas other 12 (27.9%) had a stable disease. Median progression-free survival (PFS) was 7.8 months and median overall survival (OS) was 13.9 months. We did not find any relationship with EGFR overexpression, gene amplification, while NF-kB activation was associated with a resistance to therapy. Gefitinib does not seem to increase the activity of FOLFOX in advanced colorectal cancer even in patients overexpressing EGFR or with EGFR amplification. Furthermore, while NF-kB activation seems to predict resistance to chemotherapy as demonstrated 'in vitro' models, gefitinib does not overcome this mechanism of resistance, as reported for cetuximab.

KW - Colorectal cancer

KW - Gefitinib

KW - NF-kB

UR - http://www.scopus.com/inward/record.url?scp=38049001619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38049001619&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6604121

DO - 10.1038/sj.bjc.6604121

M3 - Article

VL - 98

SP - 71

EP - 76

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 1

ER -